We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Midatech Pharma Plc | LSE:MTPH | London | Ordinary Share | GB00BNGF1L75 | ORD GBP0.02 |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 18.00 | 0.00 | 01:00:00 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 17.00 | 19.00 | ||||
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| - |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| - | O | 0 | 18.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 26/4/2023 | 07:00 | UKREG | AIM Cancellation - Biodexa Pharmaceuticals PLC |
Midatech Pharma (MTPH) Share Charts1 Year Midatech Pharma Chart |
|
1 Month Midatech Pharma Chart |
Intraday Midatech Pharma Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 27/3/2023 | 11:20 | Midatech Pharma Plc | 36 |
| 19/12/2022 | 12:20 | Midatech Pharma (MTPH) sees 10-fold increase | 2,025 |
| 24/1/2021 | 19:14 | Midatech Pharma | 4 |
| 30/4/2019 | 21:51 | Midatech Pharma (MTPH) One to Watch | 2 |
| 03/1/2017 | 12:41 | Midatech Pharma PLC | 181 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 20/12/2022 08:31 by dave4545 86119 paid 2.88p yesterday just sold for 2.42pAt 2.42p I will buy 500k, pretty sure at this rate I'll get that price with these idiot day traders bailing out |
Posted at 19/12/2022 09:40 by avenue_of_revenue Nasty MMs again messing with the spread at 20% trying to deter buyers. This will multi bag. Bought £5k in 2 lots at 2.47 and 2.69.What's the price target here guys? 5p,6p,7p,8p? |
Posted at 19/12/2022 09:19 by babbler Yup. Was deal of the day today at 2.3p. Was surprised at that open price tbh |
Posted at 19/12/2022 08:34 by avenue_of_revenue Remember paying 33p a share a few years back. 2p (£2M market cap) seems to low considering they will remain on aim and the possibility of de-listing is gone. Bought some at 2.47p |
Posted at 19/12/2022 08:04 by babbler Not delisting. Better deal done. Should get to 9lacing price of 3.3 at least now. |
Posted at 28/6/2022 08:57 by kingston78 Does anyone know whether this company has sufficient cash this year? The share price is at an all time low. Is the company going to raise funds by way of a placing? |
Posted at 01/6/2022 15:04 by manual dexterity Certainly with the cash element I would categorise both MTPH and EVG as similar and very interesting in their pipeline. Both share prices have been demolished and there is some overlay between the two.However BOTH have very interesting pipelines. Midatech Pharma PLC (AIM:MTPH) soared 32% to 13.5p after its MTX110 treatment for recurrent glioblastoma, a form of cancer, was given fast track designation by the Food and Drug Administration. The drug-delivery technology company said the fast track process will facilitate the development and accelerate the review of treatments for serious conditions. "Receiving Fast Track designation for MTX110 is an important milestone for the development of the drug as it demonstrates the need for novel and effective treatment options for this currently universally fatal disease," Dmitry Zamoryakhin, chief scientific officer, said. |
Posted at 01/6/2022 13:35 by kingston78 In August 2020 the share price had spiked to over 80 p. At its recent low of 10 p only a few days ago I did consider to buy some more shares but I did not because I didn't want to put too much money in one share. In retrospect I should have added.Nevertheless, I think the share price has potential to go much higher from here. |
Posted at 14/4/2022 12:39 by guy gibson Midatech Pharma PLC14 April 2022 14 April 2022 Midatech Pharma PLC ("Midatech" or the "Company"") Receipt of NASDAQ Notice Midatech Pharma PLC (AIM: MTPH.L; Nasdaq: MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces that it received written notification (the "Notification Letter") from The NASDAQ Stock Market LLC ("NASDAQ"), dated 13 April 2022, stating that the Company is not in compliance with the minimum bid price requirement set forth in NASDAQ's rules for continued listing on The NASDAQ Capital Market. NASDAQ Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Based on the closing bid price of the Company's American Depositary Shares (the "Depositary Shares"), each representing five ordinary shares of the Company, for the 30 consecutive business days beginning 2 March 2022, the Company no longer meets the minimum bid price requirement. The Notification Letter has no immediate effect on the listing of the Depositary Shares, and they will continue to trade on The NASDAQ Capital Market under the symbol "MTP." In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until 10 October 2022 (the "Compliance Period"), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Depositary Shares must meet or exceed $1.00 per share for at least 10 consecutive business days during the Compliance Period. If the Depositary Shares do not regain compliance with the minimum bid price requirement during the Compliance Period, the Company may be eligible for an additional grace period of 180 calendar days provided that the Company satisfies NASDAQ's initial listing standards for listing on The NASDAQ Capital Market, other than the minimum bid price requirement, and provides written notice to NASDAQ of its intention to cure the delinquency during the second grace period. If the Company does not regain compliance during the initial grace period and is not eligible for an additional grace period, NASDAQ will provide written notice that the Depositary Shares are subject to delisting from The NASDAQ Capital Market. In that event, the Company may appeal such determination to a hearing panel. The Company intends to monitor the bid price of its Depositary Shares during the Compliance Period and will consider taking such actions as may be necessary and appropriate to achieve compliance with continued listing requirements prior to the expiration of all available grace periods. The Company's business operations are not affected by the receipt of the Notification Letter. The Company's ordinary shares are listed on the AIM Market of the London Stock Exchange, and the Notification Letter does not affect the Company's compliance status with such listing. |
Posted at 09/6/2020 18:07 by mubz What is interesting is that this chap at Paul Hasting law firm- Deyan P. Spiridonov is a member of the firm's Mergers & Acquisitions practice. So have Secura Bio done this in order to trash MTPH share price and then put in a hostile bid to takeoverPlease be advised that in the event that Secura Bio refuses to withdraw its purported termination notice, Midatech and Midatech Limited will vigorously pursue any and all available remedies, including claims for monetary damages based on Secura Bio's intentional wrongdoing. Midatech and Midatech Limited also reserve all rights in law and equity against Secura Bio and its agents, including, without limitation, the right to pursue tort claims (and a recovery of fees and costs in the UK) resulting from Secura Bio's intentional efforts to cause harm to and to adversely affect Midatech's market position. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
